Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study

PLOS ONE, Dec 2019

Background and aims Controlled attenuation parameter (CAP) is a non-invasive method for measuring hepatic steatosis (HS). Non-alcoholic fatty liver disease (NAFLD) is closely related to cardiovascular diseases (CVDs). CVDs are the leading cause of morbidity and mortality in hemodialysis patients. The aim of this study was to investigate the prevalence of NAFLD in hemodialysis patients. Method We prospectively enrolled patients undergoing chronic hemodialysis, as well as patients with normal renal function who served as controls. The control group patients were referred by an endocrinologist to be tested for NAFLD; most of these patients had diabetes, hypertension, or dyslipidemia. We excluded those with excess alcohol intake, use of drugs known to induce HS, chronic viral hepatitis, or CAP failure. CAP ≥ 238 dB/m was used as a cutoff suggesting HS. An increased liver kidney contrast, as defined by ultrasound, was used to make the diagnosis of HS. Results Three hundred and forty-three hemodialysis patients and 252 control group patients were enrolled. Among the hemodialysis patients, 192 (56.0%) had CAP- or ultrasound-identified HS compared with 91 (26.5%) who only had ultrasound-identified HS (P<0.001). Among the control group patients, 212 (84.1%) had CAP- or ultrasound-identified HS compared with 180 (71.4%) who only had ultrasound-identified HS (P<0.001). Conclusions The prevalence of NAFLD in the hemodialysis patients was 56%. The number of diagnoses of NAFLD made by using CAP combined with ultrasound was more than 2 times the number made with ultrasound alone in the hemodialysis patients. Therefore, we suggest the use of CAP combined with ultrasound to screen for NAFLD in hemodialysis patients.

A PDF file should load here. If you do not see its contents the file may be temporarily unavailable at the journal website or you do not have a PDF plug-in installed and enabled in your browser.

Alternatively, you can download the file locally and open with any standalone PDF reader:

https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0176027&type=printable

Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study

April Using controlled attenuation parameter combined with ultrasound to survey non- alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study Yi-Hao Yen 0 1 Jin-Bor Chen 1 Ben-Chung Cheng 1 Jung-Fu Chen 1 Kuo-Chin Chang 0 1 Po- Lin Tseng 0 1 Cheng-Kun Wu 0 1 Ming-Chao Tsai 0 1 Ming-Tsung Lin 0 1 Tsung-Hui Hu 0 1 0 Division of Hepato-Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, 2 Division of Nephrology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, 3 Division of Endocrinology & Metabolism, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine , Kaohsiung , Taiwan 1 Editor: Han-Chieh Lin, Taipei Veterans General Hospital , TAIWAN - Data Availability Statement: All relevant data are within the paper and its Supporting Information files. Funding: This work was supported by Grant CMRPG8B1171 from Chang Gung Memorial Hospital-Kaohsiung Medical Center; Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Background and aims patients. Method Controlled attenuation parameter (CAP) is a non-invasive method for measuring hepatic steatosis (HS). Non-alcoholic fatty liver disease (NAFLD) is closely related to cardiovascular diseases (CVDs). CVDs are the leading cause of morbidity and mortality in hemodialysis patients. The aim of this study was to investigate the prevalence of NAFLD in hemodialysis We prospectively enrolled patients undergoing chronic hemodialysis, as well as patients with normal renal function who served as controls. The control group patients were referred by an endocrinologist to be tested for NAFLD; most of these patients had diabetes, hypertension, or dyslipidemia. We excluded those with excess alcohol intake, use of drugs known to induce HS, chronic viral hepatitis, or CAP failure. CAP 238 dB/m was used as a cutoff suggesting HS. An increased liver kidney contrast, as defined by ultrasound, was used to make the diagnosis of HS. Results Three hundred and forty-three hemodialysis patients and 252 control group patients were enrolled. Among the hemodialysis patients, 192 (56.0%) had CAP- or ultrasound-identified HS compared with 91 (26.5%) who only had ultrasound-identified HS (P<0.001). Among the control group patients, 212 (84.1%) had CAP- or ultrasound-identified HS compared with 180 (71.4%) who only had ultrasound-identified HS (P<0.001). Competing interests: The authors have declared that no competing interests exist. Conclusions The prevalence of NAFLD in the hemodialysis patients was 56%. The number of diagnoses of NAFLD made by using CAP combined with ultrasound was more than 2 times the number made with ultrasound alone in the hemodialysis patients. Therefore, we suggest the use of CAP combined with ultrasound to screen for NAFLD in hemodialysis patients. Introduction It is well known that cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality in chronic kidney disease patients [1±6]. In patients who undergo dialysis treatment, there are well established risk factors that contribute to the development of CVDs, including hypertension, diabetes, dyslipidemia, and being overweight [ 7 ]. Non-alcoholic fatty liver disease (NAFLD) is strongly associated with obesity, insulin resistance, hypertension, and dyslipidemia, and is now regarded as the liver manifestation of metabolic syndrome [8±10], which is a highly atherogenic condition, even at a very early age [11± 13]. Natural history studies have reported that the increased age-related mortality observed in patients with NAFLD is attributable to cardiovascular as well as liver-related deaths [ 11,14 ]. According to these observations, hemodialysis patients who develop NAFLD because of shared etiological factors (such as the components of metabolic syndrome) probably have a much faster progression of the atherosclerotic process and development of adverse CVD events than patients without NAFLD [ 15 ]. That said, the prevalence of NAFLD in patients undergoing dialysis remains unclear. However, the main risk factors responsible for the development of NAFLD are commonly observed in dialysis patients. Therefore, it is logical to expect that end-stage renal disease (ESRD) patients on maintained hemodialysis would also have a high prevalence of NAFLD. The controlled attenuation parameter (CAP) is a technology that is used to measure the degree of ultrasound (US) attenuation by hepatic fat at the central frequency of the FibroScan (Echosens, Paris, France) [ 16 ]. A FibroScan measurement is also less likely to be influenced by sampling error than a liver biopsy because it is made by exploring a liver volume approximately 100 times (...truncated)


This is a preview of a remote PDF: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0176027&type=printable

Yi-Hao Yen, Jin-Bor Chen, Ben-Chung Cheng, Jung-Fu Chen, Kuo-Chin Chang, Po-Lin Tseng, Cheng-Kun Wu, Ming-Chao Tsai, Ming-Tsung Lin, Tsung-Hui Hu. Using controlled attenuation parameter combined with ultrasound to survey non-alcoholic fatty liver disease in hemodialysis patients: A prospective cohort study, PLOS ONE, 2017, Volume 12, Issue 4, DOI: 10.1371/journal.pone.0176027